EAST ST. LOUIS, Ill. — (Mealey’s) Boehringer Ingelheim and plaintiff lawyers have agreed to settle state and federal lawsuits involving the anticoagulant Pradaxa for $650 million, the parties announced May 28.
Boehringer Ingelheim said the comprehensive settlement will resolve state and federal court cases in the United States. The company said it seeks to resolve about 4,000 claims.
“Boehringer Ingelheim expects most, if not all, of the plaintiffs to accept the terms of the settlement and Boehringer Ingelheim will vigorously defend against those who do not,” the company said in a press release.
Plaintiffs’ Counsel Concurs
Roger C. Denton, co-lead plaintiffs’ counsel in the Pradaxa multidistrict litigation and newly appointed lead negotiator, also said in a press release that the settlement will resolve about 4,000 claims.
Boehringer Ingelheim said in its statement that it stands by Pradaxa and that it “properly advised” health care professionals and patients about the “benefits and safety” of the drug.
“Notwithstanding our strong belief that we would prevail in these lawsuits, this settlement allows our company to avoid the distraction and uncertainty of protracted litigations over years and years,” the company said in its statement. “The U.S. litigation system is described by some as a business where lawyers run advertising campaigns to find clients,” it continued. “Furthermore, we have to consider that juries composed of lay people have to decide about very difficult scientific matters.”
“All this does not allow reliable prediction for the outcome of a huge number of individual trials and that is why we came to the tough decision to settle,” the company said.
Severe, Uncontrolled Bleeding
Pradaxa is an oral anticoagulant prescribed to prevent blood clots. Plaintiffs allege that the drug can cause severe bleeding that, unlike the anticoagulant warfarin, cannot be stopped and reversed with other drugs.
Federal litigation is centralized in an MDL in the U.S. District Court for the Southern District of Illinois.
For all of your legal news needs, please visit www.lexisnexis.com/mealeys.
Lexis.com subscribers may search all Mealey Publications.
Non-subscribers may search for Mealey Publications stories and documents at www.mealeysonline.com or visit www.Mealeys.com.
Mealey's is now available in eBook format!
For more information about LexisNexis products and solutions, connect with us through our corporate site.